VarMX Leads the Way at Major European Biotech Events with Innovative Anticoagulation Approaches

In May, VarmX, a biotech company that focuses on developing innovative approaches for reversing anticoagulation, will be attending two major events in Europe: the LSX World Congress on April 29-30 and Bio€quity Europe on May 12-14. At both events, VarmX will engage with investors and other biopharmaceutical companies.

Martijn Negen, VarmX’s SVP Global Commercial Strategy & Business Development, will participate in a panel discussion at the LSX World Congress. Additionally, he has been selected to present at Bio€quity Europe, which is organized by BioCentury and considered a key biopartnering event for the European biotech industry. If you are interested in meeting with the VarmX team at either of these upcoming events or obtaining more information, please contact info@varmx.com.

VarmX was founded in 2016 as a spin-off from Leiden University Medical Center (LUMC) by Professor Pieter Reitsma, an expert in hemostasis and thrombosis. The company’s lead compound VMX-C001 is a modified recombinant blood factor X developed for treating severe spontaneous bleeding and preventing bleeding during urgent surgeries in patients using oral factor Xa inhibitors (FXa DOACs) as anticoagulation therapy. VarmX is backed by a strong group of investors including Sound Bioventures, EIC, EQT Life Sciences (formerly LSP), Inkef, Lundbeckfonden BioCapital, Ysios Capital, BioGeneration Ventures, and InnovationQuarter.

For media inquiries about VarmX or its participation at the upcoming events